Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999

Comparative activity of garenoxacin (BMS 284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999–2001)

Published:2003-04 Issue:4 Volume:45 Page:273-278
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Jones Ronald N.,Biedenbach Douglas J.

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference23 articles.

1. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections;Ambrose;Antimicrob Agents Chemother,2001

2. Ambrose, P. G., Jones, R. N., Gajjar, D. A., Van Wart, S., Rubino, C., Ghavnani, S. M., & Grasela, D. M. (2002). Use of Monte Carlo Simulation to evaluate the antibacterial activity of garenoxacin (BMS-284756) against Gram-positive bacteria, abstr. A-1261. In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, San Diego, CA.

3. Resistance among Streptococcus pneumoniae;Appelbaum;Clin Infect Dis,2002

4. Practice guidelines for the management of community-acquired pneumonia in adults;Bartlett;Clin Infect Dis,2000

5. Comparison of the antibacterial activities of the quinolones BAY 12-8039, gatifloxacin (AM1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin;Bauernfiend;J Antimicrob Chemother,1997

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Community-acquired pneumonia: antibiotic therapy approach after the COVID-19 pandemic. A review;Consilium Medicum;2023-10-14

2. The efficacy and safety of sitafloxacin and garenoxacin for the treatment of pneumonia in elderly patients: A randomized, multicenter, open-label trial;Journal of Infection and Chemotherapy;2019-11

3. Ecotoxicity of Pharmaceuticals and Personal Care Products;Pharma-Ecology;2018-09-28

4. Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections;Auris Nasus Larynx;2012-10

5. New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas;Current Pharmaceutical Design;2012-02-01